Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Nat Med
; 11(11): 1170-2, 2005 Nov.
Article
em En
| MEDLINE
| ID: mdl-16205738
ABSTRACT
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.
Buscar no Google
Eixos temáticos:
Pesquisa_clinica
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
HIV-1
/
Ensaios Clínicos Fase II como Assunto
/
Fármacos Anti-HIV
/
Antagonistas dos Receptores CCR5
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article